ECSP003589A - Compuestos organicos - Google Patents

Compuestos organicos

Info

Publication number
ECSP003589A
ECSP003589A EC2000003589A ECSP003589A ECSP003589A EC SP003589 A ECSP003589 A EC SP003589A EC 2000003589 A EC2000003589 A EC 2000003589A EC SP003589 A ECSP003589 A EC SP003589A EC SP003589 A ECSP003589 A EC SP003589A
Authority
EC
Ecuador
Prior art keywords
organic compounds
compounds
pharmaceuticals
inflammatory
graph
Prior art date
Application number
EC2000003589A
Other languages
English (en)
Inventor
Judy Hayler
Stephen Paul Collingwood
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP003589A publication Critical patent/ECSP003589A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compuestos de la fórmula (gráfico), en forma libre o de sal , en donde X,R1,R2,R3 y R4 son como se definen en la memoria descriptiva, su preparación, y su uso como productos farmacéuticos, particularmente para el tratamiento de enfermedad inflamatoria u obstructiva de las vías aéreas.
EC2000003589A 1999-07-30 2000-07-27 Compuestos organicos ECSP003589A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9918035.8A GB9918035D0 (en) 1999-07-30 1999-07-30 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP003589A true ECSP003589A (es) 2002-02-25

Family

ID=10858317

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003589A ECSP003589A (es) 1999-07-30 2000-07-27 Compuestos organicos

Country Status (33)

Country Link
US (1) US6589950B1 (es)
EP (1) EP1200435B1 (es)
JP (2) JP2003506375A (es)
KR (1) KR100485289B1 (es)
CN (1) CN1213047C (es)
AR (1) AR029175A1 (es)
AT (1) ATE251160T1 (es)
AU (1) AU767349B2 (es)
BR (1) BR0012888A (es)
CA (1) CA2379560C (es)
CO (1) CO5180626A1 (es)
CZ (1) CZ2002299A3 (es)
DE (1) DE60005684T2 (es)
DK (1) DK1200435T3 (es)
EC (1) ECSP003589A (es)
ES (1) ES2208395T3 (es)
GB (1) GB9918035D0 (es)
HK (1) HK1046679A1 (es)
HU (1) HUP0201935A3 (es)
IL (1) IL147455A0 (es)
MX (1) MXPA02001102A (es)
MY (1) MY126862A (es)
NO (1) NO20020467L (es)
NZ (1) NZ516667A (es)
PE (1) PE20010543A1 (es)
PL (1) PL354477A1 (es)
PT (1) PT1200435E (es)
RU (1) RU2248977C2 (es)
SK (1) SK285730B6 (es)
TR (1) TR200200234T2 (es)
TW (2) TWI255268B (es)
WO (1) WO2001009134A1 (es)
ZA (1) ZA200200783B (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040800A2 (en) * 1999-11-30 2001-06-07 Parker Hughes Institute Syk localized at centrosome
FR2802091A1 (fr) * 1999-12-08 2001-06-15 Oreal Compositions pour la teinture des fibres keratiniques contenant des derives de paraphenylenediamine a groupement azetidinyle
PL359920A1 (en) 2000-09-20 2004-09-06 Merck Patent Gmbh 4-amino-quinazolines
MXPA03005696A (es) * 2000-12-21 2003-10-06 Glaxo Group Ltd Pirimidinaminas como moduladores de angiogenesis.
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
EP1465900B1 (en) * 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2476583C (en) * 2002-03-13 2011-07-05 Kristof Van Emelen Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
WO2003076401A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. Sulfonylamino-derivatives as novel inhibitors of histone deacetylase
US6897307B2 (en) 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
AU2003276125B2 (en) * 2002-06-17 2007-05-17 Smithkline Beecham Corporation Chemical process
CN101423497A (zh) * 2002-07-19 2009-05-06 记忆药物公司 作为磷酸二酯酶4抑制剂的6-氨基-1h-吲唑和4-氨基苯并呋喃化合物
IL166241A0 (en) 2002-07-29 2006-01-15 Rigel Pharmaceuticals Inc Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds
EP1444982A1 (de) * 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
JP2007502776A (ja) * 2003-08-15 2007-02-15 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｒｔｋ阻害剤としての６−置換アニリノプリン類
ES2361835T3 (es) * 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
EP1684690A4 (en) * 2003-11-06 2008-10-15 Celgene Corp METHODS OF USE AND COMPOSITIONS COMPRISING A JNK INHIBITOR FOR THE TREATMENT AND MANAGEMENT OF ASBESTOS-RELATED DISEASES AND DISORDERS
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
US8057815B2 (en) * 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US20050288290A1 (en) * 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
NZ553267A (en) 2004-07-27 2010-09-30 Sgx Pharmaceuticals Inc Pyrrolo-pyridine kinase modulators
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7452993B2 (en) 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
HRP20120327T1 (hr) 2004-07-28 2012-05-31 Janssen Pharmaceutica Nv Supstituirani indolil alkil amino derivati kao novi inhibitori histonske deacetilaze
CA2579007A1 (en) * 2004-09-10 2006-03-16 Altana Pharma Ag Ciclesonide and syk inhibitor combination and methods of use thereof
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CN100526315C (zh) * 2005-06-16 2009-08-12 浙江医药股份有限公司新昌制药厂 N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
JP2009511527A (ja) * 2005-10-13 2009-03-19 グラクソ グループ リミテッド Ｓｙｋ阻害物質としてのピロロピリミジン誘導体
US7803806B2 (en) * 2005-11-03 2010-09-28 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
EP1960372B1 (en) 2005-12-15 2015-12-09 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
DK1981875T3 (da) * 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
ES2327972T3 (es) * 2006-01-19 2009-11-05 Janssen Pharmaceutica, N.V. Derivados de aminofenil como nuevos inhibidores de histona deacetilasa.
EP1979326B1 (en) 2006-01-19 2012-10-03 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
BRPI0717320A2 (pt) 2006-10-23 2013-10-22 Sgx Pharmaceuticals Inc Triazóis bicíclicos como moduladores de proteína cinase
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
JP5208123B2 (ja) * 2006-12-08 2013-06-12 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
EA019941B1 (ru) 2006-12-08 2014-07-30 АйАрЭм ЭлЭлСи Соединения и композиции в качестве ингибиторов протеинкиназы
CN101611035A (zh) 2006-12-28 2009-12-23 大正制药株式会社 吡唑并嘧啶化合物
EP2134723B1 (en) 2007-03-07 2017-07-12 Boehringer Ingelheim International GmbH 2,6 diamino-9h-purine derivatives and their use in the treatment of proliferative diseases
WO2008124848A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN101289449A (zh) * 2007-04-20 2008-10-22 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和应用
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
US20090156594A1 (en) * 2007-05-21 2009-06-18 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
TW200908968A (en) * 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
US7705004B2 (en) 2007-08-17 2010-04-27 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
FR2929851B1 (fr) * 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
BRPI0910668A2 (pt) 2008-04-22 2019-09-24 Portola Pharmaceutiacals Inc inibidores de proteína quinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JP2011523646A (ja) 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
WO2010003084A2 (en) * 2008-07-02 2010-01-07 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
AU2010331927B2 (en) * 2009-12-17 2013-10-10 Merck Canada Inc. Aminopyrimidines as Syk inhibitors
EP2516434B1 (en) * 2009-12-23 2015-05-27 Takeda Pharmaceutical Company Limited Fused heteroaromatic pyrrolidinones as syk inhibitors
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
AU2012250517B2 (en) 2011-05-04 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
AU2012253885A1 (en) 2011-05-10 2013-10-31 Merck Sharp & Dohme Corp. Aminopyrimidines as Syk inhibitors
WO2012154518A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Bipyridylaminopyridines as syk inhibitors
CA2834062A1 (en) 2011-05-10 2012-11-15 Merck Sharp & Dohme Corp. Pyridyl aminopyridines as syk inhibitors
AU2012262021B2 (en) * 2011-06-01 2016-07-28 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2012177714A1 (en) 2011-06-22 2012-12-27 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
WO2013052391A1 (en) 2011-10-05 2013-04-11 Merck Sharp & Dohme Corp. PHENYL CARBOXAMIDE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US8987456B2 (en) 2011-10-05 2015-03-24 Merck Sharp & Dohme Corp. 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
EP2763976B1 (en) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP2782579B1 (en) 2011-11-23 2019-01-02 Portola Pharmaceuticals, Inc. Pyrazine kinase inhibitors
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
EP2863913B1 (en) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolyl analogs as syk inhibitors
WO2013192088A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED DIAZINE AND TRIAZINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9376418B2 (en) 2012-06-22 2016-06-28 Merck Sharp & Dohme Corp. Substituted pyridine spleen tyrosine kinase (SYK) inhibitors
EP2884982B1 (en) 2012-08-20 2017-09-20 Merck Sharp & Dohme Corp. SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
WO2014048065A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Triazolyl derivatives as syk inhibitors
EP2931281B1 (en) 2012-12-12 2018-01-17 Merck Sharp & Dohme Corp. Amino-pyrimidine-containing spleen tyrosine kinase inhibitors
EP2934525B1 (en) 2012-12-21 2019-05-08 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EP2988744A4 (en) 2013-04-26 2016-11-02 Merck Sharp & Dohme THIAZOLSUBSTITUTED AMINOHETEROARYLE AS MILZTYROSINKINASE INHIBITOR
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
CN104418858B (zh) * 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
WO2015094997A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9670196B2 (en) 2013-12-20 2017-06-06 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as Spleen Tyrosine Kinase inhibitors
EP3083559B1 (en) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
WO2015138273A1 (en) 2014-03-13 2015-09-17 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
RU2570113C1 (ru) * 2014-12-08 2015-12-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук N-(2-ацетамидопурин-6-ил)глицин, обладающий противотуберкулезной активностью
US10913744B2 (en) 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
RU2018106663A (ru) * 2015-07-24 2019-08-26 Глэксо Груп Лимитед Лечение витилиго
WO2017181285A1 (en) 2016-04-21 2017-10-26 The Royal Institution For The Advancement Of Learning/Mcgill University Purine compounds and method for the treatment of cancer
CN110300590A (zh) * 2016-10-21 2019-10-01 林伯士拉克许米公司 Tyk2抑制剂及其用途
AU2018350683A1 (en) 2017-10-19 2020-04-02 Bayer Animal Health Gmbh Use of fused heteroaromatic pyrrolidones for treatment and prevention of diseases in animals
EP3814354B1 (en) * 2018-06-22 2023-11-08 The Royal Institution for the Advancement of Learning / McGill University Purine compounds and method for the treatment of cancer
US12098117B2 (en) 2018-12-11 2024-09-24 Duke University Compositions and methods for the treatment of cancer
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529497A1 (de) * 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
FI943798A7 (fi) * 1992-02-19 1994-08-18 Pfizer Kasvaimenvastaisen vaikutuksen lisäämiseen tarkoitettuja heterosyklisi ä yhdisteitä
PT633886E (pt) * 1992-04-03 2001-03-30 Upjohn Co Aminas biciclicas-heterociclicas farmaceuticamente activas
US5550132A (en) * 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
CN1066147C (zh) * 1995-11-01 2001-05-23 诺瓦提斯公司 嘌呤衍生物及其制备方法
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
WO1999007705A1 (en) 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
PE20010543A1 (es) 2001-05-14
JP2007217426A (ja) 2007-08-30
DE60005684D1 (de) 2003-11-06
RU2248977C2 (ru) 2005-03-27
CN1365360A (zh) 2002-08-21
HUP0201935A2 (hu) 2002-11-28
NZ516667A (en) 2004-05-28
DE60005684T2 (de) 2004-07-29
WO2001009134A1 (en) 2001-02-08
EP1200435B1 (en) 2003-10-01
US6589950B1 (en) 2003-07-08
KR100485289B1 (ko) 2005-04-27
JP2003506375A (ja) 2003-02-18
MXPA02001102A (es) 2002-08-20
AU6567700A (en) 2001-02-19
AR029175A1 (es) 2003-06-18
CZ2002299A3 (cs) 2002-04-17
SK285730B6 (sk) 2007-07-06
ZA200200783B (en) 2003-04-30
ES2208395T3 (es) 2004-06-16
BR0012888A (pt) 2002-04-09
CO5180626A1 (es) 2002-07-30
CN1213047C (zh) 2005-08-03
EP1200435A1 (en) 2002-05-02
TWI274754B (en) 2007-03-01
MY126862A (en) 2006-10-31
TW200524932A (en) 2005-08-01
HUP0201935A3 (en) 2005-02-28
TWI255268B (en) 2006-05-21
CA2379560A1 (en) 2001-02-08
SK1262002A3 (en) 2002-07-02
GB9918035D0 (en) 1999-09-29
PL354477A1 (en) 2004-01-26
PT1200435E (pt) 2004-02-27
DK1200435T3 (da) 2004-02-02
AU767349B2 (en) 2003-11-06
NO20020467L (no) 2002-03-20
HK1046679A1 (zh) 2003-01-24
KR20020015394A (ko) 2002-02-27
IL147455A0 (en) 2002-08-14
CA2379560C (en) 2009-09-29
TR200200234T2 (tr) 2002-06-21
NO20020467D0 (no) 2002-01-29
ATE251160T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
ECSP067077A (es) Derivados de pirrolopiridina y su uso como antagonistas de crth2
AR029175A1 (es) Derivados 2-amino-fenilpurina, un proceso para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la preparacion de un medicamento
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
UY29633A1 (es) Derivados de oxindol
ECSP055531A (es) "nuevos derivados de glicósido de tiofeno, metodos para la preparacion de los mismos, medicamentos que comprenden dichos compuestos, y su uso"
ATE260275T1 (de) Substituierte thien-3-yl- sulfonylamino(thio)carbonyl-triazolin(thi)one
ECSP066311A (es) Derivados de la piperazina y su uso como agentes terapéuticos
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
ECSP105253A (es) Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa
AR022469A1 (es) Uso de acidos isoxazolcarboxilicos sustituidos y derivados y nuevas sustancias
CY1115719T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
CY1111022T1 (el) Νεοι φαρμακευτικοι συνδυασμοι για τη θεραπεια νοσων των αναπνευστικων οδων
GT200500360A (es) Compuestos organicos
UY29149A1 (es) Tiazolil-dihidro-indazoles
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
CR7195A (es) Nuevos derivados de oxazolidinonas como antibacterianos
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
ECSP034561A (es) Derivados puente de piperazina
PA8589801A1 (es) Aminoalcoxiindoles
SE0003476D0 (sv) Compounds
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
UY28622A1 (es) Agentes antibacterianos de quinolona
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización